All Oncology News

Gilead will voluntarily withdraw the United States indication for sacituzumab govitecan in metastatic urothelial cancer.

The CHMP issued a positive opinion recommending the approval of ribociclib plus endocrine therapy in HR+/HER2– early breast cancer at high risk of recurrence.

The South Korean Ministry of Food and Drug Safety approved selinexor plus bortezomib and dexamethasone for pretreated patients with multiple myeloma.

Jill Gilbert, MD, highlights a recent landmark decision by the FDA concerning trial design moving forward for cancer drugs.

Atrium Health Levine Cancer will begin treating patients with proton beam therapy.

Hidehito Horinouchi, MD, PhD, discusses safety data from the ALINA trial of adjuvant alectinib in ALK-positive non–small cell lung cancer.

Belzupacap sarotalocan produced complete responses in patients with low-grade non–muscle-invasive bladder cancer.

Fred Saad, MD, FRCS, discusses efficacy and safety data for darolutamide plus ADT in metastatic hormone-sensitive prostate cancer.

Cabozantinib plus atezolizumab did not produce superior OS outcomes vs a second novel hormonal therapy in metastatic castration-resistant prostate cancer.

Ashraf Z. Badros, MBCHB, discusses the use of daratumumab plus lenalidomide as maintenance therapy after transplant in newly diagnosed multiple myeloma.

Updated RAMP 201 data will support an NDA submission to the FDA for avutometinib plus defactinib in recurrent low-grade serous ovarian cancer.

Tafasitamab plus lenalidomide followed by tafasitamab monotherapy has been approved in Mexico for ASCT-ineligible, relapsed/refractory DLBCL.

Jian Q. “Michael” Yu, MD, FRCPC, FACNM, is Chief of Nuclear Medicine/PET at Fox Chase, which was recently named Philadelphia’s first Comprehensive Radiopharmaceutical Therapy Center of Excellence.

Jorge Cortes, MD, details how asciminib could affect care for patients with CML, diving into key takeaways from the ASC4FIRST trial.

Oncology experts share notable clinical trials and up-and-coming therapies presented at the 2024 ESMO Congress.

Nancy U. Lin, MD, discusses findings from the DESTINY-Breast12 trial of trastuzumab deruxtecan in advanced HER2-positive breast cancer with brain metastases.

Screening for donor-derived clonal hematopoiesis may have prognostic value for outcomes following auto-HSCT in patients with hematologic malignancies.

Retreatment with venetoclax plus rituximab generated responses in patients with CLL who had responded to and progressed after initial venetoclax treatment.

Study featured at ASTRO 2024 is one of the first to assess single-fraction SBRT for centrally located lung cancers

Adding savolitinib to osimertinib produced clinically meaningful responses in EGFR-mutant, MET-overexpressed NSCLC following progression on osimertinib.

The European Commission has granted orphan medicinal product designation to VCN-01 for the treatment of patients with retinoblastoma.

The use of patient-reported outcome measures—the gold standard in quality measurement—is crucial to building a patient-centered, value-based care system.

The FDA has granted rare pediatric disease designation to galinpepimut-S for acute myeloid leukemia.

Thierry André, MD, discusses findings from subgroup analyses of the CheckMate 8HW trial of nivolumab/ipilimumab in dMMR/MSI-H metastatic colorectal cancer.

The FDA has approved Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel in metastatic non–small cell lung cancer.

A new study from researchers at Fox Chase Cancer Center has found that some ossifying fibromyxoid tumors are malignant sarcomas.

Jacqueline Brown, MD, discusses the nuanced potential role of immunotherapy-ADC and dual-ADC combinations in bladder cancer.

The FDA has granted orphan drug designation to IMM-1-104 for pancreatic cancer.

LP-184 has received fast track designation from the FDA for the treatment of patients with glioblastoma.

Toripalimab has been approved in India and China’s Hong Kong Special Administrative Region for recurrent or metastatic nasopharyngeal carcinoma.